



# Radial Artery Versus Right Internal Thoracic Artery Versus Saphenous Vein as the Second Conduit for Coronary Artery Bypass Surgery: A Network Meta-Analysis of Clinical Outcomes

Mario Gaudino MD;\* Roberto Lorusso, MD, PhD;\* Mohamed Rahouma, MD; Ahmed Abouarab, MD; Derrick Y. Tam, MD; Cristiano Spadaccio, MD; Gaëlle Saint-Hilary, MS; Jeremy Leonard, MD; Mario Iannaccone, MD; Fabrizio D'Ascenzo, MD; Antonino Di Franco, MD; Giovanni Soletti, MD; Mohamed K. Kamel, MD; Christopher Lau, MD; Leonard N. Girardi, MD; Thomas A. Schwann, MD; Umberto Benedetto, MD; David P. Taggart, MD; Stephen E. Fremes, MD

**Background**—There remains uncertainty regarding the second-best conduit after the internal thoracic artery in coronary artery bypass grafting. Few studies directly compared the clinical results of the radial artery (RA), right internal thoracic artery (RITA), and saphenous vein (SV). No network meta-analysis has compared these 3 strategies.

**Methods and Results**—MEDLINE and EMBASE were searched for adjusted observational studies and randomized controlled trials comparing the RA, SV, and/or RITA as the second conduit for coronary artery bypass grafting. The primary end point was all-cause long-term mortality. Secondary end points were operative mortality, perioperative stroke, perioperative myocardial infarction, and deep sternal wound infection (DSWI). Pairwise and network meta-analyses were performed. A total of 149 902 patients (4 randomized, 31 observational studies) were included (RA, 16 201, SV, 112 018, RITA, 21 683). At NMA, the use of SV was associated with higher long-term mortality compared with the RA (incidence rate ratio, 1.23; 95% CI, 1.12–1.34) and RITA (incidence rate ratio, 1.26; 95% CI, 1.17–1.35). The risk of DSWI for SV was similar to RA but lower than RITA (odds ratio, 0.71; 95% CI, 0.55–0.91). There were no differences for any outcome between RITA and RA, although DSWI trended higher with RITA (odds ratio, 1.39; 95% CI, 0.92–2.1). The risk of DSWI in bilateral internal thoracic artery studies was higher when the skeletonization technique was not used.

**Conclusions**—The use of the RA or the RITA is associated with a similar and statistically significant long-term clinical benefit compared with the SV. There are no differences in operative risk or complications between the 2 arterial conduits, but DSWI remains a concern with bilateral ITA when skeletonization is not used. (*J Am Heart Assoc.* 2019;8:e010839. DOI: 10.1161/JAHA.118.010839.)

**Key Words:** arterial conduits • coronary artery bypass • coronary artery bypass graft surgery • saphenous vein graft

One of the most important unresolved questions in contemporary coronary artery bypass (CABG) surgery is the choice of the conduit to complement the internal thoracic to left anterior descending artery anastomosis.

The radial artery (RA), the right internal thoracic artery (RITA), and the saphenous vein (SV) are all currently being used routinely, although the majority of the surgeons favor the SV.

From the Department of Cardio-Thoracic Surgery, Weill Cornell Medicine, New York, NY (M.G., M.R., A.A., J.L., A.D.F., G.S., M.K.K., C.L., L.N.G.); Department of Cardio-Thoracic Surgery, Heart & Vascular Centre, Maastricht University Medical Hospital and CARIM (Cardiovascular Research Institute Maastricht), Maastricht, The Netherlands (R.L.); Schulich Heart Centre, Sunnybrook Health Science, University of Toronto, Canada (D.Y.T., S.E.F.); Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom (C.S.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (C.S.); Department of Mathematical Sciences, Politecnico di Torino, Turin, Italy (G.S.-H.); Department of Cardiology, "Città della Scienza e della Salute", University of Turin, Italy (M.I., F.D.); University of Toledo Medical Center, Toledo, OH (T.A.S.); School of Clinical Sciences, Bristol Heart Institute, University of Bristol, United Kingdom (U.B.); University of Oxford, United Kingdom (D.P.T.).

Accompanying Tables S1 through S4 and Figures S1 through S5 are available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.118.010839>

\*Dr Gaudino and Dr Lorusso contributed equally to this work.

**Correspondence to:** Mario Gaudino, MD, Department of Cardio-Thoracic Surgery, Weill Cornell Medicine, 525 E 68th St, New York, NY 10065. E-mail: [mfg9004@med.cornell.edu](mailto:mfg9004@med.cornell.edu)

Received September 2, 2018; accepted November 27, 2018.

© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

## Clinical Perspective

### What Is New?

- The use of the radial artery or the right internal thoracic artery is associated with a similar and statistically significant long-term clinical benefit compared with the saphenous vein.
- There are no differences in operative risk or complications between the two arterial conduits, but deep sternal wound infection remains a concern with bilateral internal thoracic artery when skeletonization is not used.

### What Are the Clinical Implications?

- The results of our study support the superiority of the use of a second arterial over venous graft, and suggest the equivalence in long-term and perioperative outcomes among RITA and radial artery.

Abundant observational evidence suggests a survival benefit for the use of arterial grafts, and the current guidelines encourage a wider use of the RA or the RITA, especially in patients with a long life expectancy.<sup>1–4</sup> However, the reported benefit of arterial grafts has not been confirmed in a large randomized controlled trial (RCT), and it has been hypothesized that the survival benefit seen in observational studies may be due to unmatched confounders and treatment allocation bias.<sup>5,6</sup> An important additional unresolved question is the relative role of the RITA and RA. Although the RITA is biologically identical to the left internal thoracic artery, data comparing the patency rate and clinical outcome of the 2 arterial grafts has been contradictory and inconclusive.<sup>7,8</sup>

Network meta-analysis (NMA) with adjusted indirect comparison among treatments is a useful technique to reduce the potential for heterogeneity or allocation biases, in particular when analyzing both RCTs and observational studies.<sup>9</sup>

To date, the only published NMA comparing the SV, RITA and RA as the second conduit in CABG focused only on angiographic patency and not on clinical outcomes.<sup>10</sup> Due to the well-known discrepancy between occlusion of grafts to non-left anterior descending arteries and clinical outcomes,<sup>11</sup> a similar analysis focusing on clinical end points is of particular relevance to the surgical community.

Here, we performed an NMA with the aim to specifically investigate the differences in late survival (primary outcome) and other clinical outcomes according to the type of second graft used for CABG.

## Material and Methods

The authors declare that all supporting data are available within the article and its online supplementary files. This

systematic review and NMA follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement.<sup>12</sup>

## Data Sources and Systematic Literature Review

Ovid's version of MEDLINE and EMBASE were searched from inception to February 2018 (full search strategy attached in Table S1). Inclusion criteria were English language publications, adjusted or matched observational studies or RCTs comparing RA and/or SV and/or RITA as the second conduit for CABG. In addition, we searched recent meta-analyses and reviews on this topic for potential additional studies. All citations were reviewed by 3 investigators independently (A.A., A.D.F., and M.R.), and any disagreements were resolved by consensus. In case of overlapping studies, the largest series were included.

## Data Extraction and Quality Assessment

Data extraction was performed independently by 2 investigators (A.A. and A.D.F.). The following variables were included: study demographics (sample size, number of centers, institutions involved, publication year, study period, design and country, length of follow-up), patient demographics (age, sex, diabetes mellitus, and ejection fraction) and procedural (use of skeletonization) and postoperative data. The quality of the included studies was assessed by the Newcastle–Ottawa Scale (Table S2).<sup>13</sup> Only RCTs and observational studies of high quality (Newcastle–Ottawa Scale score >6) were included in the final analysis.

## Outcomes

The primary outcome was all-cause long-term mortality. The secondary outcomes were operative mortality, perioperative stroke, perioperative myocardial infarction (MI), and deep sternal wound infection (DSWI), as defined in the original articles.

Two levels of analyses were conducted for all outcomes: (1) pairwise meta-analysis between arterial grafts (with either RITA or RA) and SV and between RITA and RA, and (2) network meta-analyses between RITA, RA, and SV.

## Data Synthesis and Analysis

### Pairwise meta-analysis

Late outcomes were pooled as the natural logarithm of the incident rate ratio (IRR) to account for potentially different follow-up durations between the groups. We estimated the IRR through several means depending on the available study data. When hazard ratios for matched (preferentially)/adjusted cohorts were provided, we took the natural logarithm

of the hazard ratio; the standard error was derived from the 95% CI or log rank *P* value.<sup>14</sup> When Kaplan–Meier curves were present, we estimated the event rates from the curves using GetData Graph Digitizer software 2.26 (<http://getdata-graph-digitizer.com/>). In case of missing Kaplan–Meier curves, we used the reported event rates in order to calculate the IRR, as previously described.<sup>15,16</sup> Short-term binary outcomes were pooled using log odds ratio (OR) with 95% CI using the generic inverse variance method.<sup>9</sup> Random effect meta-analysis was performed using meta and metafor packages in R (version 3.3.3 R Project for Statistical Computing).<sup>17,18</sup> Heterogeneity was reported as low ( $I^2=0-25\%$ ), moderate ( $I^2=26-50\%$ ), or high ( $I^2 >50\%$ ).<sup>19</sup> In random-effects meta-analysis, the extent of variation among the effects observed in different studies (between-study variance) is referred to as  $\tau^2$  (ie, the variance of the true effect size parameters across the population of studies).  $\tau^2$  reflects the amount of true variance (heterogeneity), while  $\tau$  is the estimated standard deviation of underlying true effects across studies, and they are used to describe the distribution of true effects; if there is no variance between studies,  $\tau^2$  is low (or zero).<sup>20-22</sup> We reported  $\tau^2$  values throughout tables and figures, as appropriate.

Sensitivity analysis using leave-one-out analysis and publication bias assessment by funnel plot and Egger's test were conducted for the primary outcome. Subgroup analysis was used to compare the relative results of RITA and RA versus SV. Meta-regression was used to explore the effect of age, sex, diabetes mellitus, and preoperative ejection fraction on the IRR for the primary outcome.

### Network meta-analysis

Network (multiple-treatment) meta-analysis was conducted in R (version 3.3.3 R Project for Statistical Computing) using the "netmeta" statistical package based on the method described by Rücker.<sup>23-25</sup> Inconsistency was evaluated with Cochran's *Q*.<sup>26</sup> Pooled log IRRs with 95% CIs was used to determine the relative effect estimates of late outcomes. ORs with 95% CIs were used for the binary outcomes. A random-effects model was preferentially used to improve the model fit, but results using a fixed model were also reported.

Inconsistency in NMA was evaluated by conducting conventional pairwise meta-analyses and testing consistency by comparing the direct and indirect evidence. The consistency equation used was  $\mu_{BC} = \mu_{AC} - \mu_{AB}$ , where  $\mu_{AB}$  is the treatment effect for treatment B compared with treatment A.<sup>27,28</sup> We used Cochran's *Q* statistic to assess inconsistency, and the presence of  $P < 0.05$  signifies inconsistency. Statistical significance (at the 5% level) was declared when 95% CI did not cross the line of no effect. For the primary outcome, a network meta-regression was used to relate the size of treatment effect to potential effect modifiers (mean age, percentage of female, percentage of patients with diabetes

mellitus, and mean preoperative ejection fraction). Network meta-regression was conducted using the logit transformation method with random-effects model with no priori. The logit transformation was used as suggested by other authors.<sup>29,30</sup>

## Results

### Description of the Included Studies and of the Population

A total of 2455 studies were retrieved and 35 met inclusion criteria and were included in the final meta-analysis (Figure S1). Seven studies were international and multicenter; 11 studies were from the United States; 4 from Canada, 3 each from Italy and the United Kingdom; 2 each from Japan and Australia, and 1 each from Austria, Serbia, and Argentina (Tables 1 and 2).<sup>31-65</sup>

A total of 149 902 patients were included (RA, 16 201; SV, 112 018; and RITA, 21 683) from 4 RCTs ( $n=1932$ ) and 31 observational studies ( $n=147 970$ ). Demographics of the included studies are shown in Tables 1 and 2.

The number of patients in the individual studies ranged from 182 to 48 241 (91–4577 in the RA group, 91–46 343 in the SV group, and 118–22 15 in the RITA group). The mean age ranged from 56.0 to 72.1 (56.3–72.1 years in the RA group, 57.1–70.6 years in the SV group, and 56.2–69.2 in the RITA group). Female sex ranged from 1.1 to 43.8% (1.0–43.1% in the RA group, 1.1–41.6% in the SV group, and 7.3–43.8% in the SV group). Most patients had a normal or low-normal ejection fraction (range 42–59.4%). The incidence of diabetes mellitus ranged from 5.1 to 53.2% (6.5–45.1% in the RA group, 12.0–43.8% in the SV group, and 5.1–53.3% in the RITA group).

### Pairwise Meta-Analysis

The main results of the pairwise meta-analysis are summarized in Table 3.

At a mean follow-up of 6.9 years, the use of any arterial graft (RA or RITA) was associated with lower long-term mortality compared with the use of the SV (IRR, 0.80; 95% CI, 0.75–0.85). There was a significantly higher risk of DSWI (OR 1.27; 95% CI, 1.05–1.54) in the arterial graft group. Operative mortality (OR, 0.68; 95% CI, 0.55–0.83), perioperative MI (OR, 0.77; 95% CI, 0.64–0.92) and perioperative stroke (OR, 0.80; 95% CI, 0.65–0.98) were lower in the arterial graft group.

The use of the RA was associated with lower long-term mortality (IRR, 0.81; 95% CI, 0.73–0.90) at a mean follow-up of 8.1 years compared with the SV. Operative mortality (OR, 0.66; 95% CI, 0.46–0.95) and perioperative stroke (OR, 0.73; 95% CI, 0.54–1.00) were lower in the RA group, while the risk of perioperative MI (OR, 0.67, 95% CI, 0.42–1.07), and DSWI were similar (OR, 1.10; 95% CI, 0.80–1.51).

**Table 1.** Characteristics of the Included Studies

Author/Year	Study Period	Mean/Median SD Follow-Up (Years)	Hospitals/Centers	Type
Benedetto 2013 <sup>31</sup>	1996–2012	6.4±3.6	Papworth Hospital, Cambridge, England	PSM
Benedetto 2014 <sup>32</sup>	2001–2013	4.0±3.2	Harefield Hospital, London, United Kingdom	PSM
Benedetto 2017 <sup>33</sup>	1996–2015	10.2±4.5	Bristol Heart Institute, United Kingdom	PSM
Buxton 1998 <sup>34</sup>	1985–1995	4.3	Austin and Repatriation Medical Center, University of Melbourne, Victoria, Australia	Adjusted
Calafiore 2004 <sup>35</sup>	1986–1999	Overall: 7.3±4.8 RITA: 7.1±5.0 SV: 7.5±4.7	University Hospital, Torino, Italy and “G D’Annunzio” University, Chieti, Italy	PSM
Carrier 2009 <sup>36</sup>	1995–2007	10.0	Montreal Heart Institute, Montreal, Quebec, Canada	Adjusted
Cohen 2001 <sup>37</sup>	1994–1999	Max 3.0	Sunnybrook and Women’s College Health Sciences Centre, Toronto, Canada	PSM
Dewar 1995 <sup>38</sup>	1984–1992	4.0	Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, Canada	PSM
Goldman 2011 <sup>39</sup>	2003–2009	Max 1.0	Multicenter	RCT
Goldstone 2018 <sup>40</sup>	2006–2011	Median arterial: 5.3 (IQR: 3.8–6.7) Median venous: 5.2 (IQR: 3.7–6.6)	Multicenter	PSM
Grau 2015 <sup>41</sup>	1994–2013	Overall: 10.5±5.0 RITA: 10.9±5.0 SV: 10.1±5.0	Columbia University College of Physicians and Surgeons, Ridgewood, NJ, United States	PSM
Hayward 2013 (RAPCO) <sup>42</sup>	1996–2004	6 (1.8–10.4)	University of Melbourne, Victoria, Australia	RCT
Ioannidis 2001 <sup>43</sup>	1993–1996	NR	Multicenter	Adjusted
Janiec 2017 <sup>44</sup>	2001–2015	SV: 9.3 (4.2) RA: 10.7 (4.1) RITA: 5.5 (5.0)	Multicenter	Adjusted
Kurlansky 2010 <sup>45</sup>	1972–1994	Overall: 11.0±0.5 RITA: 12±0.7.0 SV: 11.0±1.0	Florida Heart Research Institute, Miami, FL, United States	Adjusted
LaPar 2015 <sup>46</sup>	2001–2013	30.0 days	VCSQI database, Virginia, United States	PSM
Lin 2013 <sup>47</sup>	1997–2001	9.4 (5.7–11.9)	Cedars-Sinai Medical Center in Los Angeles, CA	PSM
Locker 2013 <sup>48</sup>	1993–2009	7.6	Mayo Clinic, Rochester, MN, United States	Adjusted
Lytle 2004 <sup>49</sup>	1971–1989	RITA: 16.2±2.4 SV: 16.3±2.5	The Cleveland Clinic Foundation, Cleveland, OH, United States	PSM
Nasso 2009 <sup>50</sup>	2003–2006	24.1±9.8 months	Multicenter	RCT
Navia 2016 <sup>51</sup>	1996–2014	Median: 5.5 (IQR: 2.6–8.8)	Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina	PSM
Parsa 2013 <sup>52</sup>	1984–2009	NR	Duke University Medical Center, Durham, NC, United States	Adjusted
Petrovic 2015 <sup>53</sup>	2001–2003	Max 8.0	Belgrade University School of Medicine, Belgrade, Serbia	RCT
Pusca 2008 <sup>54</sup>	1997–2006	NR	Emory University School of Medicine, Atlanta GA, United States	Adjusted
Rosenblum 2016 <sup>55</sup>	2003–2013	Median: 2.8 (1.1–4.9)	Emory University School of Medicine, Atlanta, GA, United States	PSM
Ruttman 2011 <sup>56</sup>	2001–2010	Overall: 57.7 (3.0–112.0) months RITA: 32.7 (3–111.0) RA: 67.3 (3–112.0)	Innsbruck Medical University, Austria	PSM
Santarpino 2010 <sup>57</sup>	2003–2007	3.17±0.07	Magna Graecia University of Catanzaro, Italy	Adjusted

Continued

Table 1. Continued

Author/Year	Study Period	Mean/Median SD Follow-Up (Years)	Hospitals/Centers	Type
Schwann 2016 <sup>58</sup>	1987–2011	4.7	Multicenter	PSM
Stevens 2004 <sup>59</sup>	1985–1995	Overall: 11.0±3.0 RITA: 8.0±2.0 SV: 12.0±3.0	Montreal Heart Institute, Montreal, Quebec, Canada	Adjusted
Tarelli 2001 <sup>60</sup>	1988–1990	Overall: 9.2 RITA: 9.2±2.8 SV: 9.1±2.5	Varese Hospital, Varese, Italy	PSM
Tranbaugh 2010 <sup>61</sup>	1995–2009	7.7 (0.1–13.8)	Beth Israel Medical Center, New York, NY, United States	PSM
Tranbaugh 2017 <sup>62</sup>	1995–2012	RA: 8.8±4.0 RITA: 8.9±4.9 SV: 9.1	Multicenter	Adjusted
Tsuneyoshi 2015 <sup>63</sup>	2000–2013	6.1±7.8	“Kurashiki Central Hospital, Okayama, Japan”	PSM
Yoshida 2017 <sup>64</sup>	1997–2007	7.5±4.4	Fukui Cardiovascular Center, Shinbo, Fukui, Japan	PSM
Zacharias 2004 <sup>65</sup>	1996–2002	3.7±1.9	Mercy St Vincent Medical Center, Toledo, OH, United States	PSM

IQR indicates interquartile range; NR, not reported; PSM, propensity score matched; RA, radial artery; RAPCO, Radial Artery Patency and Clinical Outcomes randomized trial; RCT, randomized controlled trial; RITA, right internal thoracic artery; SV, saphenous vein; VCSQI, Virginia Cardiac Services Quality Initiative.

The use of the RITA was associated with lower long-term mortality (IRR, 0.80; 95% CI, 0.73–0.86) at mean 8.5 years follow-up compared with SV. Perioperative MI (OR, 0.79; 95% CI, 0.65–0.96) and operative mortality (OR, 0.68; 95% CI, 0.53–0.87) were lower in the RITA arm. There was no difference in perioperative stroke (OR, 0.85; 95% CI, 0.62–1.16), while the risk of DSWI higher in the RITA group (OR, 1.33; 95% CI, 1.04–1.69).

When directly comparing the 2 arterial grafts, the use of RITA was associated with similar long-term mortality (IRR, 0.96; 95% CI, 0.83–1.11) at 7.1 years' mean follow-up compared with the RA. The risk of perioperative MI (OR, 0.32; 95% CI, 0.03–3.13) and perioperative stroke (OR, 0.87; 95% CI, 0.45–1.68) were similar between the 2 arterial grafts. There was a significantly higher risk of DSWI (OR, 2.22; 95% CI, 1.09–4.54) and operative mortality (OR, 1.76, 95% CI, 1.21–2.55) in the RITA group. When limiting the analysis to the studies where the skeletonization technique was used for ITA harvesting, no difference in DSWI between the RA and RITA groups was found (Figure S2).

A subgroup analysis for the primary outcome comparing the results of RCT versus non-RCT studies is provided in Figure S3.

Leave-one-out analysis was robust for the primary outcome in the main analysis (arterial grafts versus SV (Figure S4A). Funnel plot Egger's test intercept for the primary outcome in arterial versus venous comparison was  $-0.64 \pm 0.46$ ,  $P=0.17$  (Figure S4B).

## Network Meta-Analysis

The results of the NMA are summarized in Figure and Tables S3 and S4.

The use of the SV was associated with higher late mortality (IRR, 1.23; 95% CI, 1.12–1.34) and operative mortality (OR, 1.71; 95% CI, 1.17–2.52) compared with the RA. The risk of perioperative MI (OR, 1.32; 95% CI, 0.84–2.07), perioperative stroke (OR, 1.30; 95% CI, 0.90–1.88), and DSWI (OR, 0.98; 95% CI, 0.67–1.46) was not statistically different when compared with the RA.

The use of the SV was associated with higher late mortality (IRR, 1.26; 95% CI, 1.17–1.35), operative mortality (OR, 1.45; 95% CI, 1.14–1.84), and perioperative MI (OR, 1.30; 95% CI, 1.06–1.61) compared with the RITA. The risk of perioperative stroke (OR, 1.24; 95% CI, 0.93–1.64) was not statistically different, and the risk of DSWI (OR, 0.71; 95% CI, 0.55–0.91) was lower with the SV compared with the RITA.

The use of the RITA was associated with similar late mortality (IRR, 0.98; 95% CI, 0.89–1.07) and perioperative MI (OR, 1.01; 95% CI, 0.62–1.65) compared with the RA. There was a trend toward higher risk of DSWI in the RITA group (OR, 1.39; 95% CI, 0.92–2.1), while operative mortality and stroke were similar for the 2 arteries.

At network meta-regression, mean age, percentage of female, percentage of patients with diabetes mellitus, and mean preoperative ejection fraction were not found to significantly modify the treatment effect (Figure S5).

## Discussion

The balance between possible better long-term clinical and angiographic outcomes of arterial grafts and the potential risk of harvesting site complications and the increased technical complexity associated with their use has been the center of a continuous debate over the past 25 years.<sup>66</sup> Also, the relative

**Table 2.** Patient Demographics and Surgical Details

Author/Year	Total Number			Age, y (Mean±SD)			Sex (Female) N (%)			Ejection Fraction (Mean±SD)			COPD N (%)			Diabetes Mellitus N (%)			RA Target Vessel Stenosis (%)	OPCAB/ONCAB Details
	RA	SV	RITA	RA	SV	RITA	RA	SV	RITA	RA	SV	RITA	RA	SV	RITA	RA	SV	RITA		
RA vs SV studies																				
Benedetto 2013 <sup>31</sup>	809	809	...	64±10	65±10	...	178 (22)	157 (19.4)	...	NR	NR	...	83 (10.3)	92 (11.4)	...	82 (10.1)	98 (12.1)	...	NR	OPCAB: RA, 27.8% SV, 25.5%
Cohen 2001 <sup>37</sup>	478	956	...	60.7±8.8	61.2±8.7	...	76 (15.9)	152 (15.9)	...	NR	NR	...	40 (4.2)	23 (4.8)	...	160 (33.5)	238 (24.9)	...	NR	NR
Goldman 2011 <sup>38</sup>	366	367	...	61±8	62±8	...	1 (1)	5 (1)	...	NR	NR	...	NR	NR	...	154 (42)	153 (42)	...	>70	OPCAB: RA, 11% SV, 13%
Lin 2013 <sup>47</sup>	260	260	...	70.6±8.7	70.6±8.7	...	79 (30.4)	77 (29.4)	...	NR	NR	...	39 (15.0)	33 (12.7)	...	101 (38.8)	91 (33.5)	...	NR	OPCAB: RA, 16.5% SV, 18.1%
Patrici 2015 <sup>53</sup>	100	100	...	56.3±6.1	57.1±6.5	...	27 (27)	27 (27)	...	48.8±10.7	48.0±10.8	...	8 (8)	9 (9)	...	39 (39)	43 (43)	...	>80	NR
Santarpino 2010 <sup>57</sup>	150	180	...	72.19±9.9	70.52±9.586	...	20 (11.1)	49 (27.2)	...	53.5±9.92	49.2±10.7	...	27 (18)	24 (13.3)	...	49 (27.2)	36 (24)	...	>80	OPCAB: RA, 28.9% SV, 24%
Trenbaugh 2010 <sup>61</sup>	862	862	...	60.8±8.1	60.8±9.2	...	203 (23.5)	185 (22.5)	...	48.3±11.8	47.7±13.2	...	173 (20.1)	187 (21.7)	...	314 (36.4)	332 (38.3)	...	>70	OPCAB: RA, 4.1% SV, 1.3%
Yoshida 2017 <sup>64</sup>	91	91	...	64±8.8	64.7±9.7	...	21 (23.1%)	22 (24.2%)	...	NR	NR	...	NR	NR	...	35 (38.5)	38 (41.8)	...	87.2±13.2%	OPCAB: RA, 30.9% SV, 26.1%
Zacharias 2004 <sup>65</sup>	925	925	...	63±10	63±10	...	268 (28.1)	271 (28.5)	...	49±10	49±10	...	174 (18.3)	177 (18.6)	...	326 (34.2)	327 (34.3)	...	From <70 to >80	NR
RITA vs SV studies																				
Benedetto 2014 <sup>32</sup>	...	750	...	...	NR (Ranges)	NR (Ranges)	...	(21.2)	(10.8)	...	<50% in 22.1%	<50% in 13.2%	...	10.6	7.7	...	31.5	15.9	...	OPCAB: RITA, 71.7% SV, 72.5%
Buxton 1998 <sup>34</sup>	...	1557	...	...	64.9±9	58.6±9	...	(22)	(10.6)	...	<50% in 24.2%	<50% in 4.9%	...	NR	NR	...	19.9	6.8	...	NR
Calafore 2004 <sup>35</sup>	...	570	...	...	60.8±9.0	60.7±8.3	...	(17.5)	(19.3)	...	59.3±13.8	58.4±13.1	...	3	2.8	...	24.2	24.2	...	OPCAB: RITA, 32.5% SV, 24.2%
Carrier 2009 <sup>36</sup>	...	5420	...	...	68±8	61±9	...	29	16	...	NR	NR	...	NR	NR	...	31	21	...	NR
Dewar 1995 <sup>38</sup>	...	765	...	...	NR	NR	...	16.6	15.4	...	NR	NR	...	NR	NR	...	19.3	17.7	...	NR
Grau 2015 <sup>41</sup>	...	1006	...	...	62±9	60±9	...	12.1	10.4	...	50±12	51±11	...	5.9	5.1	...	13.3	11	...	OPCAB: RITA, 49.2% SV, 49.2%
Ioannidis 2001 <sup>38</sup>	...	830	...	...	65.2 (9.9)	62.0±10.3	...	37.3	22.6	...	42.0 (13.1)	46.5±13.7	...	19.3	13	...	38.4	25.6	...	All OPCAB
Kuriansky 2010 <sup>45</sup>	...	2369	...	...	67.5±9.4	62.9±10.0	...	25.7	14.9	...	CAT	CAT	...	NR	NR	...	27.3	20.8	...	All OPCAB
LaPar 2015 <sup>46</sup>	...	1333	...	...	59±10	56±10	...	18.7	14.3	...	55 (50-60)	55 (50-60)	...	11.4	10.7	...	34.9	18.2	...	NR
Lyle 2004 <sup>49</sup>	...	1152	...	...	57.8±8.3	57.5±8.1	...	14	12	...	NR	NR	...	NR	NR	...	12	12	...	NR
Navia 2016 <sup>51</sup>	...	485	...	...	NR	63.7±9.1	...	NR	9.8	...	NR	NR	...	NR	4.2	...	NR	25.9	...	ONCAB: RITA, 0.4% SV, 61%

Continued

Table 2. Continued

Author/Year	Total Number		Age, y (Mean±SD)			Sex (Female) N (%)			Ejection Fraction (Mean±SD)			COPD N (%)			Diabetes Mellitus N (%)			RA Target Vessel Stenosis (%)	OPCAB/ONCAB Details
	RA	SV	RA	SV	RITA	RA	SV	RITA	RA	SV	RITA	RA	SV	RITA	RA	SV	RITA		
Parsa 2013 <sup>52</sup>	...	16 881	...	64 (median)	59 (median)	...	28.5	19.8	52% (median)	51% (median)	...	...	8.2	3.9	...	29.9	14.7	NR	NR
Pusca 2008 <sup>54</sup>	...	10 212	...	62.9 (10.7)	56.0±0.34	...	28.10 (27.9)	17.4	50.1 (12.7)	51.6±11.4	...	...	1564 (15.3)	12	...	3725 (36.5)	25.2	OPCAB: SV, 39% RITA, 90%	OPCAB: SV, 39% RITA, 90%
Rosenblum 2016 <sup>55</sup>	...	306	...	63.8±10.6	59.0±10.1	...	28.7	15.5	51.7±12.4	52.2±11.0	...	...	6.3	1.8	...	43.8	27.6	ONCAB: SV, 33.7% RITA, 18.8%	ONCAB: SV, 33.7% RITA, 18.8%
Stevens 2004 <sup>56</sup>	...	2547	...	63±9	57±9	...	25	12	NR	NR	...	...	6	4	...	18	12	NR	NR
Tarelli 2001 <sup>60</sup>	...	150	...	59.3±8.3	56.5±8.2	...	17.3	7.3	54.5±13.5	57.2±13.6	...	...	NR	NR	...	24.7	11.3	NR (presumably all ONCAB)	NR (presumably all ONCAB)
RA vs RITA studies																			
Benedetto 2017 <sup>53</sup>	764	...	764	...	57±9	53 (6.9)	...	54 (7.1)	CAT	CAT	...	36.47	...	38.50	49 (6.5)	...	39 (5.1)	OPCAB: RA, 69% RITA, 44.9%	OPCAB: RA, 69% RITA, 44.9%
Hayward 2013 (RAPCO) <sup>52</sup>	198	...	196	...	59.5 (36.2-70.9)	23 (12)	...	18 (9)	NR	NR	...	NR	...	NR	22 (11%)	...	20 (10%)	All ONCAB	All ONCAB
Rutman 2011 <sup>56</sup>	277	...	277	...	56.6±9.6	28 (10.1)	...	28 (10.1)	52.9±12.1	54.9±10.8	...	92 (33.2)	...	92	62 (22.4)	...	59 (21.3)	NR	NR
Tsuneyoshi 2015 <sup>58</sup>	118	...	118	...	66.3±8	30 (25)	...	22 (19)	CAT	CAT	...	2 (1.6)	...	2 (1.6)	53 (45)	...	63 (53)	All OPCAB	All OPCAB
RA vs SV vs RITA studies																			
Goldstone 2018 <sup>61</sup>	4268	5813	1574	...	62.1±10.5	614 (14.5)	916 (15.8)	229 (14.3)	55.5±12.0	56.1±12.0	629 (14.8)	856 (14.7)	250 (15.6)	1525 (35.7)	2066 (35.5)	528 (33.7)	NR	NR	NR
Janic 2017 <sup>44</sup>	1036	46 343	862	...	64.5 (9.7)	277 (26.7%)	8879 (19.2%)	146 (16.9%)	CAT	CAT	39 (5.7%)	2551 (6.9%)	59 (7.7%)	212 (20.7%)	11 077 (24.3%)	206 (24.0%)	NR	OPCAB: SV, 2.4% RA, 2.4% RITA 6.7%	OPCAB: SV, 2.4% RA, 2.4% RITA 6.7%
Locker 2013 <sup>48</sup>	169	1153 (Matched)	589	...	NR	NR	187 (16.2)	NR	58±13	NR	NR	86 (7.5)	NR	NR	221 (19.2)	NR	NR	OPCAB: SV, 4.4% MultiArt, 3.3%	OPCAB: SV, 4.4% MultiArt, 3.3%
Messò 2009 <sup>50</sup>	202	202	201	...	70.5±3.1	87 (43.1)	84 (41.6)	88 (43.8)	CAT	CAT	57 (28.2)	56 (27.7)	55 (27.4)	73 (36.1)	77 (38.1)	76 (37.8)	>70	All ONCAB	All ONCAB
Schwann 2016 <sup>58</sup>	551	551	551	...	58.4±10.2	72 (13)	97 (18)	77 (14)	52±10	59±11	46 (6.3)	39 (7.1)	41 (7.4)	100 (18)	94 (17)	93 (17)	>75	ONCAB: RITA, 98% RA, 96% SV, 95%	ONCAB: RITA, 98% RA, 96% SV, 95%
Tranbaugh 2010 <sup>61</sup>	4577	7073	1674	...	60.3±9.7	1033 (22.6)	2448 (34.6)	460 (27.5)	49.1±10.9	46.4±14.3	781 (17.1)	1804 (25.5)	149 (8.9)	702 (37.2)	2704 (38.2)	597 (35.7)	LCX>70 RCA>90	OPCAB: SV, 3.5% RA, 3.0% RITA, 1.4%	OPCAB: SV, 3.5% RA, 3.0% RITA, 1.4%

CAT indicates reported as categories; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; EF, ejection fraction; LCX, left circumflex artery territory; MultiArt, multiple arterial grafting group; NR, not reported; ONCAB, on-pump coronary artery bypass; OPCAB, off-pump coronary artery bypass; RA, radial artery; RCA, right coronary artery territory; RITA, right internal thoracic artery; SV, saphenous vein.

**Table 3.** Outcomes Summary of the Pairwise Meta-Analysis

Model	Studies*	Point Estimate <sup>†</sup>	95% CI	Overall Effect (Z-Value, P Value)	Heterogeneity (I <sup>2</sup> , P Value)	Tau <sup>2</sup>	Interpretation
<b>Long term mortality</b>							
RA/SV	11	0.81	0.73 to 0.90	...	47, 0.04	0.0110	Better in RA
RITA/SV	17	0.80	0.73 to 0.86	...	73, <0.01	0.0136	Better in RITA
RITA/RA	9	0.96	0.83 to 1.11	...	57, 0.02	0.0204	ND
ART/SV	28	0.80	0.75 to 0.85	-6.93, <0.0001	66, <0.01	0.0115	Better in ART
<b>Perioperative DSWI</b>							
RA/SV	8	1.10	0.80 to 1.51	...	0, 0.48	0	ND
RITA/SV	14	1.33	1.04 to 1.69	...	24, 0.20	0.0463	Higher in RITA
RITA/RA	6	2.22	1.09 to 4.54	...	40, 0.14	0.2795	Higher in RITA
ART/SV	21	1.27	1.05 to 1.54	2.41, 0.0159	14, 0.27	0.0264	Higher in ART
<b>Perioperative mortality</b>							
RA/SV	7	0.66	0.46 to 0.95	-2.27, 0.0234	29, 0.21	0.0599	Better in RA
RITA/SV	17	0.68	0.53 to 0.87	-3.11, 0.0019	56,	0.1327	Better in RITA
RITA/RA	7	1.76	1.21 to 2.55	2.98, 0.0029	11.7, 0.34	0.0310	Better in RA
ART/SV	24	0.68	0.55 to 0.83	-3.79, 0.0002	49.1, 0.004	0.1043	Better in ART
<b>Perioperative stroke</b>							
RA/SV	7	0.73	0.54 to 1.00	...	0, 0.72	0	Better in RA
RITA/SV	11	0.85	0.62 to 1.16	...	36, 0.11	0.0875	ND
RITA/RA	5	0.87	0.45 to 1.68	...	29, 0.23	0.1653	ND
ART/SV	18	0.80	0.65 to 0.98	-2.11, 0.0350	14, 0.29	0.0266	Better in arterial
<b>Perioperative MI</b>							
RA/SV	7	0.67	0.42 to 1.07	...	0, 0.56	0	ND
RITA/SV	8	0.79	0.65 to 0.96	...	0, 0.65	0	Better in RITA
RITA/RA	2	0.32	0.03 to 3.13	...	61.1, 0.11	1.67	ND
ART/SV	15	0.77	0.64 to 0.92	-2.82, 0.0048	0, 0.73	0	Better in ART

ART indicates all arterial grafts; DSWI, deep sternal wound infections; MI, myocardial infarction; ND, no difference; RA, radial artery; RITA, right internal thoracic artery; SV, saphenous vein.

\*Articles reporting the outcomes in RA, RITA, and SV cohorts were included as 3 studies (RA/SV, RITA/SV, and RITA/RA).

<sup>†</sup>Incidence rate ratio was used for long-term mortality, while odds ratio was used for operative mortality and perioperative outcomes.

efficacy of the RITA and RA as the second arterial grafts remains controversial.<sup>7</sup>

Several pairwise meta-analyses on the topic have been published previously.<sup>1,67,68</sup> However, pairwise meta-analyses have known limitations in terms of heterogeneity of the included studies and potential for treatment allocation bias. NMAs have been proposed to overcome the limitations of the pairwise comparison, especially when summarizing the evidence of RCTs and observational studies.<sup>9,69</sup> It has been suggested that NMA can be superior to classical pairwise analyses, especially in case of comparison of a new treatment to a standard one.<sup>70</sup>


This is the first NMA specifically addressing the differences in clinical outcomes according to the type of second graft used for CABG. The only published network meta-analysis on

the subject focused only on the patency rates of conduits and did not include clinical outcomes.<sup>10</sup> Due to the demonstrated absence of a consistent correlation between angiographic failure and clinical events,<sup>11</sup> a deeper understanding of the clinical impact of the type of second conduit used for CABG seems of major relevance.

The results of our study support the superiority of the use of a second arterial over venous graft, and suggest the equivalence in long-term and perioperative outcomes between the RITA and RA.

The superior midterm patency rate of arterial grafts (especially the RA) has been convincingly demonstrated in RCTs and observational studies.<sup>50,71-74</sup> A large amount of observational evidence also suggests a clinical benefit in terms of survival and event-free survival for the use of the RA





**Figure.** Full network meta-analytic estimates (expressed as incidence rate ratio [IRR] and odds ratio [OR] with 95% credible interval) for the different outcomes using random and fixed models respectively. **A**, Long-term mortality (SV is associated with higher long-term mortality compared with RA; IRR=1.23, 95%CI=1.12–1.34;  $\tau^2=0.0127$ ;  $I^2=64\%$ ); **B**, Operative mortality (SV is associated with higher operative mortality compared with RA expressed as OR, 1.71; 95% CI. 1.17–2.52;  $\tau^2=0.1219$ ;  $I^2=48.7\%$ ); **C**, Perioperative MI (SV is associated with similar perioperative MI compared with RA expressed as OR=1.32, 95%CI=0.84–2.07;  $\tau^2=0.0041$ ;  $I^2=2.1\%$ ); **D**, Perioperative stroke (SV is associated with similar perioperative stroke compared with RA expressed as OR=1.30, 95%CI=0.90–1.88;  $\tau^2=0.0573$ ;  $I^2=22\%$ ); **E**, Perioperative DSWI (SV is associated with similar perioperative DSWI compared with RA expressed as OR=0.98, 95%CI=0.67–1.46;  $\tau^2=0.0671$ ;  $I^2=25.4\%$ ). DSWI indicates deep sternal wound infections; MI, myocardial infarction; RA, radial artery; RITA, right internal thoracic artery; SV, saphenous vein.

or the RITA instead of the SV as the second graft.<sup>1,7,75,76</sup> However, we have recently shown how unmatched confounders are present even in the best comparative observational studies and suggested that a treatment allocation bias may be responsible for the better clinical outcome of patients receiving more than 1 arterial graft.<sup>6</sup>

This type of bias is potentially present even in the present meta-analysis, but the additional power and precision of NMA in defining relations and interactions between treatments from the aggregated estimates of all the available evidence should permit a more efficient comparison among different strategies.<sup>9</sup>

Our results are in line with those of a recent patient-level meta-analysis on the comparison between the RA and the SV.<sup>76</sup> However, at first sight, our results appear to contradict the overall neutral findings of the ART (Arterial Revascularization Trial), where on the primary intention-to-treat analysis, there was no difference in survival between single and bilateral ITA grafts at 10 years (in press). However, 40% of patients in the ART received a different treatment from that initially proposed and an as-treated analysis showed a

significant survival benefit in patients receiving >1 arterial graft, consistent with the results of the current study. Difference in sample size and length of follow-up and the fact that in observational studies the revascularization strategy is based on surgical judgment and not mandated by protocol are possible explanations for these apparent contradictions.

A key finding of this study is the demonstration of equivalence between the RITA and RA with respect to all the short- and long-term clinical outcomes. Of note, in our analysis, the relative survival benefit of the RITA and RA compared with the SV were identical (SV versus RITA and RA, IRR, 1.26; 95% CI, 1.17–1.35). Although there was a trend toward higher risk of DSWI with RITA, this risk became nonsignificant in a subgroup analysis of studies where the skeletonization of ITA was employed. This finding is in accordance with what was reported by previous meta-analyses<sup>7</sup> and by a post hoc analysis of the ART.<sup>77</sup>

The literature on the comparison between the RITA and RA is discordant. We previously published a pairwise meta-analysis of the propensity-matched studies comparing the 2

arterial grafts and found that the use of the RITA was associated with a 25% relative reduction in the risk of long-term mortality.<sup>7</sup> The reason underlying the discrepancy between our previous meta-analysis and the present findings is probably related to the different sample size (149 902 patients with 6.9 years of follow-up for the present analysis versus 15 374 patients and a range of 45–168 months of follow-up for the previous pairwise comparison). Also, our previous analysis did not include 2 recent large studies comparing the 2 arterial grafts.<sup>33,78</sup> Finally, the use of NMA and direct/indirect comparisons allow for better precision around estimates compared with pairwise comparisons.

Of note, in a large study the Society of Thoracic Surgeons National Database of >1.4 million patients, Schwann et al<sup>8</sup> showed significantly higher perioperative mortality and risk of DSWI using the RITA, but not the RA, versus the SV as the second graft—findings that were also demonstrated in the present study. The authors also described a significant volume-to-outcome relation for the use of the RITA but not of the RA. Similarly, in a meta-analysis of 34 bilateral internal thoracic artery (BITA) series and 27 000 BITA patients, we recently identified a highly significant BITA use-to-outcome relationship for long-term survival and incidence of DSWI that was independent from the well-known CABG volume/outcome effect.<sup>78</sup> These findings suggest that BITA grafting may be more technically demanding than the use of the single internal thoracic artery and that a volume/outcome relation can explain the marginally increased operative risk in the RITA arm.

A key point when using the RA for CABG is the degree of target vessel stenosis. It has been shown that the patency rate of RA grafts is strongly influenced by the degree of target coronary stenosis.<sup>79–81</sup> In fact, a target vessel stenosis >70% was a common criterion for using the RA in the studies included in this meta-analysis (Table 2).

This study shares the usual limitations of meta-analyses of observational studies.<sup>82</sup> Despite statistical adjustment and the use of NMA, between-studies heterogeneity remains a source of bias. Important details such as the etiology of follow-up of death, the protocols used to reduce the risk of DSWI (with the exception of skeletonization of the ITA), and the incidence of repeat revascularization were not systematically retrievable and could not be included in our analyses.

Additionally, we recognize that despite including only adjusted studies, the presence of unmeasured confounders and treatment allocation biases cannot be excluded.<sup>6</sup> However, the NMA approach utilized and the low-moderate-grade heterogeneity found across the studies should have attenuated these biases.

In conclusion, in an NMA of adjusted observational and randomized studies comparing the RA, the RITA, and the SV as the second conduit for CABG, we found that the use of the

RITA or the RA was associated with a similar long-term clinical benefit compared with the use of the SV. No differences in late and operative mortality and postoperative complications was found between the 2 arterial conduits, although DSWI remains a concern after BITA grafting if skeletonization is not used.

## Disclosures

None.

## References

- Buttar SN, Yan TD, Taggart DP, Tian DH. Long-term and short-term outcomes of using bilateral internal mammary artery grafting versus left internal mammary artery grafting: a meta-analysis. *Heart*. 2017;103:1419–1426.
- Authors/Task Force Members, Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann F-J, Richter DJ, Schaeuble P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J*. 2014;35:2541–2619.
- Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O’Gara PT, Sabatine MS, Smith PK, Smith SC. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. *Circulation*. 2016;134:e123–e155.
- Aldea GS, Bakaeen FG, Pal J, Femes S, Head SJ, Sabik J, Rosengart T, Kappetein AP, Thourani VH, Firestone S, Mitchell JD; Society of Thoracic Surgeons. The Society of Thoracic Surgeons clinical practice guidelines on arterial conduits for coronary artery bypass grafting. *Ann Thorac Surg*. 2016;101:801–809.
- Taggart DP, Altman DG, Gray AM, Lees B, Gerry S, Benedetto U, Flather M; ART Investigators. Randomized trial of bilateral versus single internal-thoracic-artery grafts. *N Engl J Med*. 2016;375:2540–2549.
- Gaudino M, Di Franco A, Rahouma M, Tam DY, Iannaccone M, Deb S, D’Ascenzo F, Abouarab AA, Girardi LN, Taggart DP, Femes SE. Unmeasured confounders in observational studies comparing bilateral versus single internal thoracic artery for coronary artery bypass grafting: a meta-analysis. *J Am Heart Assoc*. 2018;7:e008010. DOI: 10.1161/JAHA.117.008010.
- Benedetto U, Gaudino M, Caputo M, Tranbaugh RF, Lau C, Di Franco A, Ng C, Girardi LN, Angelini GD. Right internal thoracic artery versus radial artery as the second best arterial conduit: insights from a meta-analysis of propensity-matched data on long-term survival. *J Thorac Cardiovasc Surg*. 2016;152:1083–1091.e15.
- Schwann TA, Habib RH, Wallace A, Shahian DM, O’Brien S, Jacobs JP, Puskas JD, Kurlansky PA, Engoren MC, Tranbaugh RF, Bonnell MR. Operative outcomes of multiple-arterial versus single-arterial coronary bypass grafting. *Ann Thorac Surg*. 2018;105:1109–1119.
- Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. *J Clin Epidemiol*. 2008;61:455–463.
- Benedetto U, Raja SG, Albanese A, Amrani M, Biondi-Zoccai G, Frati G. Searching for the second best graft for coronary artery bypass surgery: a network meta-analysis of randomized controlled trials. *Eur J Cardiothorac Surg*. 2015;47:59–65; discussion 65.
- Gaudino M, Antoniadis C, Benedetto U, Deb S, Di Franco A, Di Giammarco G, Femes S, Glineur D, Grau J, He G-W, Marinelli D, Ohmes LB, Patrono C, Puskas

- J, Tranbaugh R, Girardi LN, Taggart DP; ATLANTIC (Arterial Grafting International Consortium) Alliance. Mechanisms, consequences, and prevention of coronary graft failure. *Circulation*. 2017;136:1749–1764.
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med*. 2009;151:W65–W94.
  13. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M. Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalysis. 3rd Symp Syst Rev Basics Improv Qual Impact. 2000.
  14. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Stat Med*. 1998;17:2815–2834.
  15. Yanagawa B, Verma S, Jüni P, Tam DY, Mazine A, Puskas JD, Friedrich JO. A systematic review and meta-analysis of in situ versus composite bilateral internal thoracic artery grafting. *J Thorac Cardiovasc Surg*. 2017;153:1108–1116.e16.
  16. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials*. 2007;8:16.
  17. Schwarzer G. meta: an R package for meta-analysis. *R News*. 2007;7:40–45.
  18. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Softw*. 2010;36:1–48.
  19. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327:557–560.
  20. Deeks J, Higgins J, Altman DG. Analysing data and undertaking meta-analyses. In: Sally G, Julian H, eds. *Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series*. England: John Wiley & Sons; 2008:243–296.
  21. Borenstein M, Hedges L, Higgins J, Rothstein H. *Introduction to Meta-Analysis*. West Sussex, England: John Wiley & Sons; 2009.
  22. Borenstein M, Hedges L, Rothstein H. A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Methods*. 2010;1:97–111.
  23. Rucker G, Schwarzer G, Krahn U, König J. Netmeta: network meta-analysis using frequentist methods. R package version 0.9-7. [Internet]. 2017. Available at: <https://CRAN.R-project.org/package=netmeta>. Accessed September 3, 2018.
  24. Rucker G, Schwarzer G, König J. Netmeta: network meta-analysis with R. Version 0.6-0 2014. 12. [Internet]. 2014. Available at: <http://cran.r-project.org/web/packages/netmeta/index.html>. Accessed September 3, 2018.
  25. Rucker G. Network meta-analysis, electrical networks and graph theory. *Res Synth Methods*. 2012;3:312–324.
  26. Krahn U, Binder H, König J. A graphical tool for locating inconsistency in network meta-analyses. *BMC Med Res Methodol*. 2013;13:35.
  27. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. *Stat Med*. 1996;15:2733–2749.
  28. Higgins JP. Identifying and addressing inconsistency in network meta-analysis. Cochrane comparing multiple interventions methods group Oxford training event. 2013; Available at: <https://methods.cochrane.org/sites/methods.coc hrane.org.cmi/files/public/uploads/S9-L%20Identifying%20and%20addressing%20inconsistency%20in%20network%20meta-analysis.pdf>. Accessed September 3, 2018.
  29. Qin G, Hotilovac L. Comparison of non-parametric confidence intervals for the area under the ROC curve of a continuous-scale diagnostic test. *Stat Methods Med Res*. 2008;17:207–221.
  30. Snell KI, Ensor J, Debray TP, Moons KG, Riley RD. Meta-analysis of prediction model performance across multiple studies: which scale helps ensure between-study normality for the C-statistic and calibration measures? *Stat Methods Med Res*. 2018;27:3505–3522.
  31. Benedetto U, Codispoti M. Age cutoff for the loss of survival benefit from use of radial artery in coronary artery bypass grafting. *J Thorac Cardiovasc Surg*. 2013;146:1078–1084; discussion 1084–1085.
  32. Benedetto U, Amrani M, Gaer J, Bahrami T, de Robertis F, Simon AR, Raja SG; Harefield Cardiac Outcomes Research Group. The influence of bilateral internal mammary arteries on short- and long-term outcomes: a propensity score matching in accordance with current recommendations. *J Thorac Cardiovasc Surg*. 2014;148:2699–2705.
  33. Benedetto U, Caputo M, Gaudino M, Marsico R, Rajakaruna C, Bryan A, Angelini GD. Right internal thoracic artery or radial artery? A propensity-matched comparison on the second-best arterial conduit. *J Thorac Cardiovasc Surg*. 2017;153:79–88.e4.
  34. Buxton BF, Komeda M, Fuller JA, Gordon I. Bilateral internal thoracic artery grafting may improve outcome of coronary artery surgery. Risk-adjusted survival. *Circulation*. 1998;98:111–116.
  35. Calafiore AM, Di Giammarco G, Teodori G, Di Mauro M, Iacò AL, Bivona A, Contini M, Vitolla G. Late results of first myocardial revascularization in multiple vessel disease: single versus bilateral internal mammary artery with or without saphenous vein grafts. *Eur J Cardiothorac Surg*. 2004;26:542–548.
  36. Carrier M, Cossette M, Pellerin M, Hébert Y, Bouchard D, Cartier R, Demers P, Jeanmart H, Pagé P, Perrault LP. Statin treatment equalizes long-term survival between patients with single and bilateral internal thoracic artery grafts. *Ann Thorac Surg*. 2009;88:789–795; discussion 795.
  37. Cohen G, Tamariz MG, Sever JY, Liaghati N, Guru V, Christakis GT, Bhatnagar G, Cutrara C, Abouzahr L, Goldman BS, Fremes SE. The radial artery versus the saphenous vein graft in contemporary CABG: a case-matched study. *Ann Thorac Surg*. 2001;71:180–185; discussion 185–186.
  38. Dewar LR, Jamieson WR, Janusz MT, Adeli-Sardo M, Germann E, MacNab JS, Tyers GF. Unilateral versus bilateral internal mammary revascularization. Survival and event-free performance. *Circulation*. 1995;92:118–113.
  39. Goldman S, Sethi GK, Holman W, Thai H, McFalls E, Ward HB, Kelly RF, Rhenman B, Tobler GH, Bakaev FG, Huh J, Soltero E, Moursi M, Haime M, Crittenden M, Kasirajan V, Ratliff M, Pett S, Irimpen A, Gunnar W, Thomas D, Fremes S, Moritz T, Reda D, Harrison L, Wagner TH, Wang Y, Planting L, Miller M, Rodriguez Y, Juneman E, Morrison D, Pierce MK, Kreamer S, Shih M-C, Lee K. Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: a randomized trial. *JAMA*. 2011;305:167–174.
  40. Goldstone AB, Chiu P, Baiocchi M, Wang H, Lingala B, Boyd JH, Woo YJ. Second arterial versus venous conduits for multivessel coronary artery bypass surgery in California. *Circulation*. 2018;137:1698–1707.
  41. Grau JB, Johnson CK, Kuschner CE, Ferrari G, Shaw RE, Brizzio ME, Zapolanski A. Impact of pump status and conduit choice in coronary artery bypass: a 15-year follow-up study in 1412 propensity-matched patients. *J Thorac Cardiovasc Surg*. 2015;149:1027–1033.e2.
  42. Hayward PA, Buxton BF. Mid-term results of the Radial Artery Patency and Clinical Outcomes randomized trial. *Ann Cardiothorac Surg*. 2013;2:458–466.
  43. Ioannidis JP, Galanos O, Katritsis D, Connery CP, Drossos GE, Swistel DG, Anagnostopoulos CE. Early mortality and morbidity of bilateral versus single internal thoracic artery revascularization: propensity and risk modeling. *J Am Coll Cardiol*. 2001;37:521–528.
  44. Janiec M, Dimberg A, Nazari Shafiqi TZ, Lagerqvist B, Lindblom RPF. No improvements in long-term outcome after coronary artery bypass grafting with arterial grafts as a second conduit: a Swedish nationwide registry study. *Eur J Cardiothorac Surg*. 2018;53:448–454.
  45. Kurlansky PA, Traad EA, Dorman MJ, Galbut DL, Zucker M, Ebra G. Thirty-year follow-up defines survival benefit for second internal mammary artery in propensity-matched groups. *Ann Thorac Surg*. 2010;90:1011–108.
  46. LaPar DJ, Crosby IK, Rich JB, Quader MA, Speir AM, Kern JA, Tribble C, Kron IL, Ailawadi G; Investigators for the Virginia Cardiac Surgery Quality Initiative. Bilateral internal mammary artery use for coronary artery bypass grafting remains underutilized: a propensity-matched multi-institution analysis. *Ann Thorac Surg*. 2015;100:8–14; discussion 14–15.
  47. Lin J, Cheng W, Czer LS, De Robertis MA, Mirocha J, Ruzza A, Kass RM, Khoynzhad A, Ramzy D, Esmailian F, Trento A. Coronary artery bypass graft surgery using the radial artery as a secondary conduit improves patient survival. *J Am Heart Assoc*. 2013;2:e000266. DOI: 10.1161/JAHA.113.000266.
  48. Locker C, Schaff HV, Dearani JA, Daly RC. Improved late survival with arterial revascularization. *Ann Cardiothorac Surg*. 2013;2:467–474.
  49. Lytle BW, Blackstone EH, Sabik JF, Houghtaling P, Loop FD, Cosgrove DM. The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years. *Ann Thorac Surg*. 2004;78:2005–2012; discussion 2012–2014.
  50. Nasso G, Coppola R, Bonifazi R, Piancone F, Bozzetti G, Speziale G. Arterial revascularization in primary coronary artery bypass grafting: direct comparison of 4 strategies—results of the Stand-in-Y Mammary Study. *J Thorac Cardiovasc Surg*. 2009;137:1093–1100.
  51. Navia DO, Vrancic M, Piccinini F, Camporrotondo M, Dorsa A, Espinoza J, Benzadon M, Camou J. Myocardial revascularization exclusively with bilateral internal thoracic arteries in T-graft configuration: effects on late survival. *Ann Thorac Surg*. 2016;101:1775–1781.
  52. Parsa CJ, Shaw LK, Rankin JS, Daneshmand MA, Gaca JG, Milano CA, Glower DD, Smith PK. Twenty-five-year outcomes after multiple internal thoracic artery bypass. *J Thorac Cardiovasc Surg*. 2013;145:970–975.
  53. Petrovic I, Nezic D, Peric M, Milojevic P, Djokic O, Kosevic D, Tasic N, Djukanovic B, Otasevic P. Radial artery vs saphenous vein graft used as the second conduit for surgical myocardial revascularization: long-term clinical follow-up. *J Cardiothorac Surg*. 2015;10:127.
  54. Pusca SV, Kilgo PD, Vega JD, Cooper WA, Vassiliades TA, Chen EP, Lattouf OM, Guyton RA, Puskas JD. Propensity-score analysis of early outcomes after

- bilateral versus single internal thoracic artery grafting. *Innovations (Phila)*. 2008;3:19–24.
55. Rosenblum JM, Harskamp RE, Hoedemaker N, Walker P, Liberman HA, de Winter RJ, Vassiliades TA, Puskas JD, Halkos ME. Hybrid coronary revascularization versus coronary artery bypass surgery with bilateral or single internal mammary artery grafts. *J Thorac Cardiovasc Surg*. 2016;151:1081–1089.
  56. Ruttman E, Fischler N, Sakic A, Chevtchik O, Alber H, Schistek R, Ulmer H, Grimm M. Second internal thoracic artery versus radial artery in coronary artery bypass grafting: a long-term, propensity score-matched follow-up study. *Circulation*. 2011;124:1321–1329.
  57. Santarpino G, Onorati F, Cristodoro L, Scalas C, Mastroberto P, Renzulli A. Radial artery graft flowmetry is better than saphenous vein on postero-lateral wall. *Int J Cardiol*. 2010;143:158–164.
  58. Schwann TA, Hashim SW, Badour S, Obeid M, Engoren M, Tranbaugh RF, Bonnell MR, Habib RH. Equipoise between radial artery and right internal thoracic artery as the second arterial conduit in left internal thoracic artery-based coronary artery bypass graft surgery: a multi-institutional study. *Eur J Cardiothorac Surg*. 2016;49:188–195.
  59. Stevens LM, Carrier M, Perrault LP, Hébert Y, Cartier R, Bouchard D, Fortier A, El-Hamamsy I, Pellerin M. Single versus bilateral internal thoracic artery grafts with concomitant saphenous vein grafts for multivessel coronary artery bypass grafting: effects on mortality and event-free survival. *J Thorac Cardiovasc Surg*. 2004;127:1408–1415.
  60. Tarelli G, Mantovani V, Maugeri R, Chelazzi P, Vanoli D, Grossi C, Ornaghi D, Panisi P, Sala A. Comparison between single and double internal mammary artery grafts: results over ten years. *Ital Heart J*. 2001;2:423–427.
  61. Tranbaugh RF, Dimitrova KR, Friedmann P, Geller CM, Harris LJ, Stelzer P, Cohen B, Hoffman DM. Radial artery conduits improve long-term survival after coronary artery bypass grafting. *Ann Thorac Surg*. 2010;90:1165–1172.
  62. Tranbaugh RF, Schwann TA, Swistel DG, Dimitrova KR, Al-Shaar L, Hoffman DM, Geller CM, Engoren M, Balaran SK, Puskas JD, Habib RH. Coronary artery bypass graft surgery using the radial artery, right internal thoracic artery, or saphenous vein as the second conduit. *Ann Thorac Surg*. 2017;104:553–559.
  63. Tsuneyoshi H, Komiya T, Shimamoto T, Sakai J, Hiraoka T, Kawashima T, Muraoka G, Fujimoto M, Yamanaka K. The second best arterial graft to the left coronary system in off-pump bypass surgery: a propensity analysis of the radial artery with a proximal anastomosis to the ascending aorta versus the right internal thoracic artery. *Gen Thorac Cardiovasc Surg*. 2015;63:335–342.
  64. Yoshida S, Numata S, Tsutsumi Y, Monta O, Yamazaki S, Seo H, Samura T, Ohashi H. Short- and long-term results of radial artery and saphenous vein grafts in the right coronary system: a propensity-matched study. *Surg Today*. 2017;47:335–343.
  65. Zacharias A, Habib RH, Schwann TA, Riordan CJ, Durham SJ, Shah A. Improved survival with radial artery versus vein conduits in coronary bypass surgery with left internal thoracic artery to left anterior descending artery grafting. *Circulation*. 2004;109:1489–1496.
  66. Dai C, Lu Z, Zhu H, Xue S, Lian F. Bilateral internal mammary artery grafting and risk of sternal wound infection: evidence from observational studies. *Ann Thorac Surg*. 2013;95:1938–1945.
  67. Yi G, Shine B, Rehman SM, Altman DG, Taggart DP. Effect of bilateral internal mammary artery grafts on long-term survival: a meta-analysis approach. *Circulation*. 2014;130:539–545.
  68. Takagi H, Goto S, Watanabe T, Mizuno Y, Kawai N, Umemoto T. A meta-analysis of adjusted hazard ratios from 20 observational studies of bilateral versus single internal thoracic artery coronary artery bypass grafting. *J Thorac Cardiovasc Surg*. 2014;148:1282–1290.
  69. Greco T, Landoni G, Biondi-Zoccai G, D'Ascenzo F, Zangrillo A. A Bayesian network meta-analysis for binary outcome: how to do it. *Stat Methods Med Res*. 2016;25:1757–1773.
  70. Chalmers I, Matthews R. What are the implications of optimism bias in clinical research? *Lancet*. 2006;367:449–450.
  71. Gaudino M, Tondi P, Benedetto U, Milazzo V, Flore R, Glieda F, Ponziani FR, Luciani N, Girardi LN, Crea F, Masetti M. Radial artery as a coronary artery bypass conduit: 20-year results. *J Am Coll Cardiol*. 2016;68:603–610.
  72. Buxton BF, Raman JS, Ruengsakulrach P, Gordon I, Rosalion A, Bellomo R, Horrigan M, Hare DL. Radial artery patency and clinical outcomes: five-year interim results of a randomized trial. *J Thorac Cardiovasc Surg*. 2003;125:1363–1371.
  73. Glineur D, D'hoore W, de Kerchove L, Noirhomme P, Price J, Hanet C, El Khoury G. Angiographic predictors of 3-year patency of bypass grafts implanted on the right coronary artery system: a prospective randomized comparison of gastroepiploic artery, saphenous vein, and right internal thoracic artery grafts. *J Thorac Cardiovasc Surg*. 2011;142:980–988.
  74. Deb S, Cohen EA, Singh SK, Une D, Laupacis A, Fremes SE; RAPS Investigators. Radial artery and saphenous vein patency more than 5 years after coronary artery bypass surgery: results from RAPS (Radial Artery Patency Study). *J Am Coll Cardiol*. 2012;60:28–35.
  75. Taggart DP, Altman DG, Flather M, Gerry S, Gray A, Lees B, Benedetto U; ART (Arterial Revascularization Trial) Investigators. Associations between adding a radial artery graft to single and bilateral internal thoracic artery grafts and outcomes: insights from the Arterial Revascularization Trial. *Circulation*. 2017;136:454–463.
  76. Gaudino M, Benedetto U, Fremes S, Biondi-Zoccai G, Sedrakyan A, Puskas JD, Angelini GD, Buxton B, Frati G, Hare DL, Hayward P, Nasso G, Moat N, Peric M, Yoo KJ, Speziale G, Girardi LN, Taggart DP; RADIAL Investigators. Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery. *N Engl J Med*. 2018;378:2069–2077.
  77. Benedetto U, Altman DG, Gerry S, Gray A, Lees B, Pawlaczyk R, Flather M, Taggart DP; Arterial Revascularization Trial Investigators. Pedicled and skeletonized single and bilateral internal thoracic artery grafts and the incidence of sternal wound complications: insights from the Arterial Revascularization Trial. *J Thorac Cardiovasc Surg*. 2016;152:270–276.
  78. Gaudino M, Bakaee F, Benedetto U, Rahouma M, Di Franco A, Tam D, Iannaccone M, Schwann T, Habib R, Ruel M, Puskas J, Sabik J, Girardi L, Taggart D, Fremes S. Use rate and outcome in bilateral internal thoracic artery grafting: insights from a systematic review and meta-analysis. *J Am Heart Assoc*. 2018;7:e009361. DOI: 10.1161/JAHA.118.009361.
  79. Maniar HS, Sundt TM, Barner HB, Prasad SM, Peterson L, Absi T, Moustakidis P. Effect of target stenosis and location on radial artery graft patency. *J Thorac Cardiovasc Surg*. 2002;123:45–52.
  80. Hashimoto H, Isshiki T, Ikari Y, Hara K, Saeki F, Tamura T, Yamaguchi T, Suma H. Effects of competitive blood flow on arterial graft patency and diameter. Medium-term postoperative follow-up. *J Thorac Cardiovasc Surg*. 1996;111:399–407.
  81. Manninen HI, Jaakkola P, Suhonen M, Rehnberg S, Vuorenniemi R, Matsi PJ. Angiographic predictors of graft patency and disease progression after coronary artery bypass grafting with arterial and venous grafts. *Ann Thorac Surg*. 1998;66:1289–1294.
  82. Song F, Xiong T, Parekh-Bhurke S, Loke YK, Sutton AJ, Eastwood AJ, Holland R, Chen Y-F, Glenny A-M, Deeks JJ, Altman DG. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. *BMJ*. 2011;343:d4909.

# Supplemental Material

Table S1. Search strategy.

<b>Ovid MEDLINE® (Epub Ahead of Print, In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE® - 1946 to Present); Searched on 02/22/2018</b>	
<b>Line #</b>	<b>Search term</b>
1	Coronary Artery Bypass/
2	(aorta adj2 bypass).tw.
3	CABG.tw.
4	(aortic coronary bypass or aorticocoronary anastomosis).tw.
5	(aorto coronary adj2 (bypass or graft)).tw.
6	(aortocoronary adj2 (anastomosis or bypass or shunt or graft)).tw.
7	(coronary adj2 (bypass or graft)).tw.
8	(Total arterial revascularization or total arterial revascularisation or Multiple arterial revascularization or multiple arterial revascularisation).tw.
9	or/1-8
10	Radial Artery/
11	(radial arter* or arteria radialis or radialis artery).tw.
12	10 or 11
13	Saphenous Vein/
14	(Saphenous Vein* or SVG or saphena vein or saphenous venos system or vena saphena).tw.
15	13 or 14
16	Internal Mammary-Coronary Artery Anastomosis/
17	(Right Internal Mammary Artery or RIMA or Coronary Internal Mammary Artery or arteria mammaria interna or arteria thoracica interna or internal thoracic artery or mammary internal artery).tw.
18	(cardiac muscle revascularisation or cardiac muscle revascularization or coronary revascularisation or coronary revascularization or heart muscle revascularisation or heart myocardium revascularisation or heart revascularisation or heart revascularization or internal mammary arterial anastomosis or internal mammary arterial implantation or internal mammary artery anastomosis or internal mammary artery graft or internal mammary artery implant or internal mammary artery implantation or internal mammary-coronary artery anastomosis or myocardial revascularisation or myocardial revascularization or myocardium revascularisation or myocardium revascularization or transmyocardial laser revascularisation or transmyocardial laser revascularization or vineberg operation).tw.
19	16 or 17 or 18
20	9 and (12 or 15 or 19)

- 21 ((second or 2nd) adj3 (conduit\* or graft\*)).tw.
- 22 (multi-vessel\* or multivessel\* or multiple vessel\* or multi-vein\* or multiple vein\* or multi-arter\* or multiple arter\*).tw.
- 23 21 or 22
- 24 20 and 23
- 25 limit 24 to English language

Table S2. Newcastle-Ottawa scale for the included studies.

Author / Year	Selection	Comparability	Outcome/Exposure	Total
Benedetto 2013 <sup>1</sup>	****	**	***	*****
Benedetto 2014 <sup>2</sup>	****	**	***	*****
Benedetto 2017 <sup>3</sup>	****	**	***	*****
Buxton 1998 <sup>4</sup>	****	**	**	*****
Calafiore 2004 <sup>5</sup>	****	**	***	*****
Carrier 2009 <sup>6</sup>	****	**	***	*****
Cohen 2001 <sup>7</sup>	****	**	*	*****
Dewar 1995 <sup>8</sup>	****	**	**	*****
Goldman 2011 <sup>9</sup>	****	**	*	*****
Goldstone 2017 <sup>10</sup>	****	**	***	*****
Grau 2015 <sup>11</sup>	****	**	***	*****
Hayward 2013 (RAPCO) <sup>12</sup>	****	**	***	*****
Ioannidis 2001 <sup>13</sup>	****	**	*	*****
Janiec 2017 <sup>14</sup>	****	**	***	*****
Kurlansky 2010 <sup>15</sup>	****	**	***	*****
LaPar 2015 <sup>16</sup>	****	**	*	*****
Lin 2013 <sup>17</sup>	****	**	***	*****
Locker 2013 <sup>18</sup>	****	*	***	*****
Lytle 2004 <sup>19</sup>	****	**	***	*****
Nasso 2009 <sup>20</sup>	****	**	*	*****
Navia 2016 <sup>21</sup>	****	**	***	*****
Parsa 2013 <sup>22</sup>	****	**	***	*****
Petrovic 2015 <sup>23</sup>	****	**	***	*****
Pusca 2008 <sup>24</sup>	****	**	***	*****
Rosenblum 2016 <sup>25</sup>	****	**	***	*****
Ruttman 2011 <sup>26</sup>	****	**	**	*****
Santarpino 2010 <sup>27</sup>	****	**	***	*****
Schwann 2016 <sup>28</sup>	****	**	***	*****
Stevens 2004 <sup>29</sup>	****	**	***	*****



Tarelli 2001 <sup>30</sup>	****	**	***	*****
Tranbaugh 2010 <sup>31</sup>	****	**	***	*****
Tranbaugh 2017 <sup>32</sup>	****	**	***	*****
Tsuneyoshi 2015 <sup>33</sup>	****	**	***	*****
Yoshida 2017 <sup>34</sup>	****	**	***	*****
Zacharias 2004 <sup>35</sup>	****	**	**	*****

Table S3. Comparison of direct and indirect estimates to assess inconsistency within network loops for the outcomes.

<b>Long term mortality</b>	<p>Fixed effect model:</p> <table border="1"> <thead> <tr> <th>comparison</th> <th>k</th> <th>prop</th> <th>nma</th> <th>direct</th> <th>indir.</th> <th>Diff</th> <th>z</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>RA:RITA</td> <td>9</td> <td>0.47</td> <td>0.00</td> <td>-0.01</td> <td>0.02</td> <td>-0.03</td> <td>-0.57</td> <td>0.5712</td> </tr> <tr> <td>RA:SV</td> <td>11</td> <td>0.62</td> <td>-0.18</td> <td>-0.17</td> <td>-0.19</td> <td>0.03</td> <td>0.57</td> <td>0.5712</td> </tr> <tr> <td>RITA :SV</td> <td>17</td> <td>0.91</td> <td>-0.18</td> <td>-0.18</td> <td>-0.16</td> <td>-0.03</td> <td>-0.57</td> <td>0.5712</td> </tr> </tbody> </table> <p>Random effects model:</p> <table border="1"> <thead> <tr> <th>comparison</th> <th>k</th> <th>prop</th> <th>nma</th> <th>direct</th> <th>indir.</th> <th>Diff</th> <th>z</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>RA:RITA</td> <td>9</td> <td>0.53</td> <td>0.02</td> <td>0.03</td> <td>0.02</td> <td>0.01</td> <td>0.11</td> <td>0.9113</td> </tr> <tr> <td>RA:SV</td> <td>11</td> <td>0.65</td> <td>-0.21</td> <td>-0.21</td> <td>-0.20</td> <td>-0.01</td> <td>-0.11</td> <td>0.9113</td> </tr> <tr> <td>RITA :SV</td> <td>17</td> <td>0.82</td> <td>-0.23</td> <td>-0.23</td> <td>-0.24</td> <td>0.01</td> <td>0.11</td> <td>0.9113</td> </tr> </tbody> </table>	comparison	k	prop	nma	direct	indir.	Diff	z	p-value	RA:RITA	9	0.47	0.00	-0.01	0.02	-0.03	-0.57	0.5712	RA:SV	11	0.62	-0.18	-0.17	-0.19	0.03	0.57	0.5712	RITA :SV	17	0.91	-0.18	-0.18	-0.16	-0.03	-0.57	0.5712	comparison	k	prop	nma	direct	indir.	Diff	z	p-value	RA:RITA	9	0.53	0.02	0.03	0.02	0.01	0.11	0.9113	RA:SV	11	0.65	-0.21	-0.21	-0.20	-0.01	-0.11	0.9113	RITA :SV	17	0.82	-0.23	-0.23	-0.24	0.01	0.11	0.9113
comparison	k	prop	nma	direct	indir.	Diff	z	p-value																																																																	
RA:RITA	9	0.47	0.00	-0.01	0.02	-0.03	-0.57	0.5712																																																																	
RA:SV	11	0.62	-0.18	-0.17	-0.19	0.03	0.57	0.5712																																																																	
RITA :SV	17	0.91	-0.18	-0.18	-0.16	-0.03	-0.57	0.5712																																																																	
comparison	k	prop	nma	direct	indir.	Diff	z	p-value																																																																	
RA:RITA	9	0.53	0.02	0.03	0.02	0.01	0.11	0.9113																																																																	
RA:SV	11	0.65	-0.21	-0.21	-0.20	-0.01	-0.11	0.9113																																																																	
RITA :SV	17	0.82	-0.23	-0.23	-0.24	0.01	0.11	0.9113																																																																	
<b>Perioperative mortality</b>	<p>Fixed effect model:</p> <table border="1"> <thead> <tr> <th>comparison</th> <th>k</th> <th>prop</th> <th>nma</th> <th>direct</th> <th>indir.</th> <th>Diff</th> <th>z</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>RA:RITA</td> <td>7</td> <td>0.67</td> <td>-0.21</td> <td>-0.61</td> <td>0.61</td> <td>-1.22</td> <td>-4.23</td> <td>&lt; 0.0001</td> </tr> <tr> <td>RA:SV</td> <td>7</td> <td>0.91</td> <td>-0.61</td> <td>-0.51</td> <td>-1.73</td> <td>1.22</td> <td>2.78</td> <td>0.0054</td> </tr> <tr> <td>RITA :SV</td> <td>17</td> <td>0.98</td> <td>-0.40</td> <td>-0.41</td> <td>-0.11</td> <td>-0.30</td> <td>-0.50</td> <td>0.6182</td> </tr> </tbody> </table> <p>Random effects model:</p> <table border="1"> <thead> <tr> <th>comparison</th> <th>k</th> <th>prop</th> <th>nma</th> <th>direct</th> <th>indir.</th> <th>Diff</th> <th>z</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>RA:RITA</td> <td>7</td> <td>0.72</td> <td>-0.17</td> <td>-0.50</td> <td>0.68</td> <td>-1.18</td> <td>-2.59</td> <td>0.0095</td> </tr> <tr> <td>RA:SV</td> <td>7</td> <td>0.82</td> <td>-0.54</td> <td>-0.36</td> <td>-1.34</td> <td>0.97</td> <td>1.90</td> <td>0.0575</td> </tr> <tr> <td>RITA :SV</td> <td>17</td> <td>0.97</td> <td>-0.37</td> <td>-0.39</td> <td>0.51</td> <td>-0.90</td> <td>-1.16</td> <td>0.2459</td> </tr> </tbody> </table>	comparison	k	prop	nma	direct	indir.	Diff	z	p-value	RA:RITA	7	0.67	-0.21	-0.61	0.61	-1.22	-4.23	< 0.0001	RA:SV	7	0.91	-0.61	-0.51	-1.73	1.22	2.78	0.0054	RITA :SV	17	0.98	-0.40	-0.41	-0.11	-0.30	-0.50	0.6182	comparison	k	prop	nma	direct	indir.	Diff	z	p-value	RA:RITA	7	0.72	-0.17	-0.50	0.68	-1.18	-2.59	0.0095	RA:SV	7	0.82	-0.54	-0.36	-1.34	0.97	1.90	0.0575	RITA :SV	17	0.97	-0.37	-0.39	0.51	-0.90	-1.16	0.2459
comparison	k	prop	nma	direct	indir.	Diff	z	p-value																																																																	
RA:RITA	7	0.67	-0.21	-0.61	0.61	-1.22	-4.23	< 0.0001																																																																	
RA:SV	7	0.91	-0.61	-0.51	-1.73	1.22	2.78	0.0054																																																																	
RITA :SV	17	0.98	-0.40	-0.41	-0.11	-0.30	-0.50	0.6182																																																																	
comparison	k	prop	nma	direct	indir.	Diff	z	p-value																																																																	
RA:RITA	7	0.72	-0.17	-0.50	0.68	-1.18	-2.59	0.0095																																																																	
RA:SV	7	0.82	-0.54	-0.36	-1.34	0.97	1.90	0.0575																																																																	
RITA :SV	17	0.97	-0.37	-0.39	0.51	-0.90	-1.16	0.2459																																																																	
<b>Perioperative MI</b>	<p>Fixed effect model:</p> <table border="1"> <thead> <tr> <th>comparison</th> <th>k</th> <th>prop</th> <th>nma</th> <th>direct</th> <th>indir.</th> <th>Diff</th> <th>z</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>RA:RITA</td> <td>2</td> <td>0.11</td> <td>-0.02</td> <td>1.12</td> <td>-0.17</td> <td>1.29</td> <td>1.66</td> <td>0.0963</td> </tr> <tr> <td>RA:SV</td> <td>7</td> <td>0.90</td> <td>-0.28</td> <td>-0.40</td> <td>0.88</td> <td>-1.29</td> <td>-1.66</td> <td>0.0963</td> </tr> <tr> <td>RITA :SV</td> <td>8</td> <td>0.98</td> <td>-0.26</td> <td>-0.24</td> <td>-1.52</td> <td>1.29</td> <td>1.66</td> <td>0.0963</td> </tr> </tbody> </table> <p>Random effects model:</p> <table border="1"> <thead> <tr> <th>comparison</th> <th>k</th> <th>prop</th> <th>nma</th> <th>direct</th> <th>indir.</th> <th>Diff</th> <th>z</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>RA:RITA</td> <td>2</td> <td>0.12</td> <td>-0.01</td> <td>1.12</td> <td>-0.16</td> <td>1.28</td> <td>1.65</td> <td>0.0990</td> </tr> <tr> <td>RA:SV</td> <td>7</td> <td>0.90</td> <td>-0.28</td> <td>-0.40</td> <td>0.88</td> <td>-1.28</td> <td>-1.65</td> <td>0.0990</td> </tr> <tr> <td>RITA :SV</td> <td>8</td> <td>0.98</td> <td>-0.27</td> <td>-0.24</td> <td>-1.52</td> <td>1.28</td> <td>1.65</td> <td>0.0990</td> </tr> </tbody> </table>	comparison	k	prop	nma	direct	indir.	Diff	z	p-value	RA:RITA	2	0.11	-0.02	1.12	-0.17	1.29	1.66	0.0963	RA:SV	7	0.90	-0.28	-0.40	0.88	-1.29	-1.66	0.0963	RITA :SV	8	0.98	-0.26	-0.24	-1.52	1.29	1.66	0.0963	comparison	k	prop	nma	direct	indir.	Diff	z	p-value	RA:RITA	2	0.12	-0.01	1.12	-0.16	1.28	1.65	0.0990	RA:SV	7	0.90	-0.28	-0.40	0.88	-1.28	-1.65	0.0990	RITA :SV	8	0.98	-0.27	-0.24	-1.52	1.28	1.65	0.0990
comparison	k	prop	nma	direct	indir.	Diff	z	p-value																																																																	
RA:RITA	2	0.11	-0.02	1.12	-0.17	1.29	1.66	0.0963																																																																	
RA:SV	7	0.90	-0.28	-0.40	0.88	-1.29	-1.66	0.0963																																																																	
RITA :SV	8	0.98	-0.26	-0.24	-1.52	1.29	1.66	0.0963																																																																	
comparison	k	prop	nma	direct	indir.	Diff	z	p-value																																																																	
RA:RITA	2	0.12	-0.01	1.12	-0.16	1.28	1.65	0.0990																																																																	
RA:SV	7	0.90	-0.28	-0.40	0.88	-1.28	-1.65	0.0990																																																																	
RITA :SV	8	0.98	-0.27	-0.24	-1.52	1.28	1.65	0.0990																																																																	

	Fixed effect model:										
	comparison	k	prop	nma	direct	indir.	Diff	z	p-value		
<b>Perioperative Stroke</b>	RA:RITA	5	0.59	-0.05	-0.01	-0.09	0.08	0.22	0.8248		
	RA:SV	7	0.91	-0.24	-0.31	0.45	-0.75	-1.44	0.1489		
	SV:RITA	11	0.96	0.20	0.17	0.78	-0.61	-1.15	0.2519		
		Random effects model:									
		comparison	k	prop	nma	direct	indir.	Diff	z	p-value	
		RA:RITA	5	0.59	-0.05	0.06	-0.20	0.26	0.60	0.5485	
	RA:SV	7	0.87	-0.26	-0.34	0.26	-0.60	-1.09	0.2775		
	SV:RITA	11	0.94	0.21	0.17	0.95	-0.78	-1.25	0.2117		
	Fixed effect model:										
	comparison	k	prop	nma	direct	indir.	Diff	z	p-value		
<b>Perioperative DSWI</b>	RA:RITA	6	0.63	-0.29	-0.54	0.15	-0.69	-2.00	0.0455		
	RA:SV	8	0.86	0.00	0.09	-0.54	0.63	1.49	0.1373		
	SV:RITA	14	0.95	-0.29	-0.26	-0.79	0.54	1.28	0.2001		
		Random effects model:									
		comparison	k	prop	nma	direct	indir.	Diff	z	p-value	
		RA:RITA	6	0.62	-0.33	-0.63	0.15	-0.77	-1.80	0.0726	
	RA:SV	8	0.79	0.02	0.18	-0.60	0.78	1.59	0.1124		
	SV:RITA	14	0.94	-0.35	-0.29	-1.19	0.89	1.65	0.0987		

- k - Number of studies providing direct evidence
- prop - Direct evidence proportion
- nma - Estimated treatment effect (logIRR or log OR) in network meta-analysis
- direct - Estimated treatment effect (logIRR or log OR) derived from direct evidence
- indir. - Estimated treatment effect (logIRR or log OR) derived from indirect evidence
- Diff - Difference between direct and indirect treatment estimates
- z - z-value of test for disagreement (direct versus indirect)
- p-value - p-value of test for disagreement (direct versus indirect)


RA, radial artery; RITA, right internal artery; SV, saphenous vein.

Table S4. Rank scores with probability rank of different graft groups with the greatest reduction in outcomes within the different treatment groups (RITA, RA and SV) where the closer to one equates to the probability the therapy leads to the greatest reduction.

<b>Long term mortality</b>		P-score (fixed)	P-score (random)
	RITA	0.7875	0.8466
	RA	0.7125	0.6534
	SV	0.0000	0.0000
<b>Perioperative mortality</b>		P-score (fixed)	P-score (random)
	RA	0.9699	0.8967
	RITA	0.5301	0.6012
	SV	0.0000	0.0021
<b>Perioperative MI</b>		P-score (fixed)	P-score (random)
	RITA	0.7293	0.7361
	RA	0.7143	0.7052
	SV	0.0564	0.0587
<b>Perioperative stroke</b>		P-score (fixed)	P-score (random)
	RA	0.7746	0.7532
	RITA	0.6797	0.6704
	SV	0.0457	0.0764
<b>Perioperative DSWI</b>		P-score (fixed)	P-score (random)
	SV	0.7522	0.7638
	RA	0.7254	0.7056
	RITA	0.0224	0.0306

RA, radial artery; RITA, right internal artery; SV, saphenous vein.

Figure S1. PRISMA flow chart of study selection.



**Figure S2.** A: Forest plot showing subgroup differences for skeletonization on deep sternal wound infection (DSWI) in RITA vs RA/SVG pairwise comparisons (Subgroup difference P-value=0.1933); B: Forest plot showing subgroup differences for skeletonization on deep sternal wound infection (DSWI) in RITA vs SVG pairwise comparisons (Subgroup difference P-value=0.4194); C: Forest plot showing subgroup differences for skeletonization on deep sternal wound infection (DSWI) in RITA vs RA pairwise comparisons (Subgroup difference P-value=0.2786). RA, radial artery; RITA, right internal artery; SV, saphenous vein.




Figure S3. Long-term mortality for arterial grafts (RA/RITA) vs SV in RCT vs non-RCT trials (Subgroup difference P value=0.4897). ART; All arterial grafts, RA; radial artery, RITA; right internal thoracic artery, SV; saphenous vein.





Figure S4. Leave one out (A) and Funnel plot (B) for the primary analysis. RA, radial artery; RITA, right internal artery; SV, saphenous vein.

**A**



**B**










Figure S5. Network meta-regression for long term mortality. A: Mean age; B: Female percent; C: Diabetes mellitus percent; D: Ejection fraction (EF) percent.



## Supplemental References:

1. Benedetto U, Codispoti M. Age cutoff for the loss of survival benefit from use of radial artery in coronary artery bypass grafting. *J Thorac Cardiovasc Surg.* 2013;146:1078–1084; discussion 1084–1085.
2. Benedetto U, Amrani M, Gaer J, Bahrami T, de Robertis F, Simon AR, Raja SG, Harefield Cardiac Outcomes Research Group. The influence of bilateral internal mammary arteries on short- and long-term outcomes: a propensity score matching in accordance with current recommendations. *J Thorac Cardiovasc Surg.* 2014;148:2699–2705.
3. Benedetto U, Caputo M, Gaudino M, Marsico R, Rajakaruna C, Bryan A, Angelini GD. Right internal thoracic artery or radial artery? A propensity-matched comparison on the second-best arterial conduit. *J Thorac Cardiovasc Surg.* 2017;153:79–88.e4.
4. Buxton BF, Komeda M, Fuller JA, Gordon I. Bilateral internal thoracic artery grafting may improve outcome of coronary artery surgery. Risk-adjusted survival. *Circulation.* 1998;98:111–6.
5. Calafiore AM, Di Giammarco G, Teodori G, Di Mauro M, Iacò AL, Bivona A, Contini M, Vitolla G. Late results of first myocardial revascularization in multiple vessel disease: single versus bilateral internal mammary artery with or without saphenous vein grafts. *Eur J Cardiothorac Surg.* 2004;26:542–548.
6. Carrier M, Cossette M, Pellerin M, Hébert Y, Bouchard D, Cartier R, Demers P, Jeanmart H, Pagé P, Perrault LP. Statin treatment equalizes long-term survival between patients with single and bilateral internal thoracic artery grafts. *Ann Thorac Surg.* 2009;88:789–795; discussion 795.
7. Cohen G, Tamariz MG, Sever JY, Liaghati N, Guru V, Christakis GT, Bhatnagar G, Cutrara C, Abouzahr L, Goldman BS, Fremes SE. The radial artery versus the saphenous vein graft in contemporary CABG: a case-matched study. *Ann Thorac Surg.* 2001;71:180–185; discussion 185–186.
8. Dewar LR, Jamieson WR, Janusz MT, Adeli-Sardo M, Germann E, MacNab JS, Tyers GF. Unilateral versus bilateral internal mammary revascularization. Survival and event-free performance. *Circulation.* 1995;92:118–13.
9. Goldman S, Sethi GK, Holman W, Thai H, McFalls E, Ward HB, Kelly RF, Rhenman B, Tobler GH, Bakaeen FG, Huh J, Soltero E, Moursi M, Haime M, Crittenden M, Kasirajan V, Ratliff M, Pett S, Irimpen A, Gunnar W, Thomas D, Fremes S, Moritz T, Reda D, Harrison L, Wagner TH, Wang Y, Planting L, Miller M, Rodriguez Y, Juneman E, Morrison D, Pierce MK, Kreamer S, Shih M-C, Lee K. Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: a randomized trial. *JAMA.* 2011;305:167–174.
10. Goldstone AB, Chiu P, Baiocchi M, Wang H, Lingala B, Boyd JH, Woo YJ. Second Arterial Versus Venous Conduits for Multivessel Coronary Artery Bypass Surgery in California. *Circulation.* 2018;137:1698–1707.
11. Grau JB, Johnson CK, Kuschner CE, Ferrari G, Shaw RE, Brizzio ME, Zapolanski A. Impact of pump status and conduit choice in coronary artery bypass: A 15-year follow-up study in 1412 propensity-matched patients. *J Thorac Cardiovasc Surg.* 2015;149:1027–1033.e2.
12. Hayward PA, Buxton BF. Mid-term results of the Radial Artery Patency and Clinical Outcomes randomized trial. *Ann Cardiothorac Surg.* 2013;2:458–466.
13. Ioannidis JP, Galanos O, Katritsis D, Connery CP, Drossos GE, Swistel DG, Anagnostopoulos CE. Early mortality and morbidity of bilateral versus single internal thoracic artery revascularization: propensity and risk modeling. *J Am Coll Cardiol.* 2001;37:521–528.

14. Janiec M, Dimberg A, Nazari Shafti TZ, Lagerqvist B, Lindblom RPF. No improvements in long-term outcome after coronary artery bypass grafting with arterial grafts as a second conduit: a Swedish nationwide registry study. *Eur J Cardiothorac Surg*. 2017 Aug 28. [Epub ahead of print].
15. Kurlansky PA, Traad EA, Dorman MJ, Galbut DL, Zucker M, Ebra G. Thirty-year follow-up defines survival benefit for second internal mammary artery in propensity-matched groups. *Ann Thorac Surg*. 2010;90:101–108.
16. LaPar DJ, Crosby IK, Rich JB, Quader MA, Speir AM, Kern JA, Tribble C, Kron IL, Ailawadi G, Investigators for the Virginia Cardiac Surgery Quality Initiative. Bilateral Internal Mammary Artery Use for Coronary Artery Bypass Grafting Remains Underutilized: A Propensity-Matched Multi-Institution Analysis. *Ann Thorac Surg*. 2015;100:8–14; discussion 14–15.
17. Lin J, Cheng W, Czer LS, De Robertis MA, Mirocha J, Ruzza A, Kass RM, Khoynezhad A, Ramzy D, Esmailian F, Trento A. Coronary artery bypass graft surgery using the radial artery as a secondary conduit improves patient survival. *J Am Heart Assoc*. 2013;2:e000266. doi: 10.1161/JAHA.113.000266.
18. Locker C, Schaff HV, Dearani JA, Daly RC. Improved late survival with arterial revascularization. *Ann Cardiothorac Surg*. 2013;2:467–474.
19. Lytle BW, Blackstone EH, Sabik JF, Houghtaling P, Loop FD, Cosgrove DM. The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years. *Ann Thorac Surg*. 2004;78:2005–2012; discussion 2012–2014.
20. Nasso G, Coppola R, Bonifazi R, Piancone F, Bozzetti G, Speziale G. Arterial revascularization in primary coronary artery bypass grafting: Direct comparison of 4 strategies--results of the Stand-in-Y Mammary Study. *J Thorac Cardiovasc Surg*. 2009;137:1093–1100.
21. Navia DO, Vrancic M, Piccinini F, Camporrotondo M, Dorsa A, Espinoza J, Benzadon M, Camou J. Myocardial Revascularization Exclusively With Bilateral Internal Thoracic Arteries in T-Graft Configuration: Effects on Late Survival. *Ann Thorac Surg*. 2016;101:1775–1781.
22. Parsa CJ, Shaw LK, Rankin JS, Daneshmand MA, Gaca JG, Milano CA, Glower DD, Smith PK. Twenty-five-year outcomes after multiple internal thoracic artery bypass. *J Thorac Cardiovasc Surg*. 2013;145:970–975.
23. Petrovic I, Nezic D, Peric M, Milojevic P, Djokic O, Kosevic D, Tasic N, Djukanovic B, Otasevic P. Radial artery vs saphenous vein graft used as the second conduit for surgical myocardial revascularization: long-term clinical follow-up. *J Cardiothorac Surg*. 2015;10:127.
24. Pusca SV, Kilgo PD, Vega JD, Cooper WA, Vassiliades TA, Chen EP, Lattouf OM, Guyton RA, Puskas JD. Propensity-score analysis of early outcomes after bilateral versus single internal thoracic artery grafting. *Innovations (Phila)*. 2008;3:19–24.
25. Rosenblum JM, Harskamp RE, Hoedemaker N, Walker P, Liberman HA, de Winter RJ, Vassiliades TA, Puskas JD, Halkos ME. Hybrid coronary revascularization versus coronary artery bypass surgery with bilateral or single internal mammary artery grafts. *J Thorac Cardiovasc Surg*. 2016;151:1081–1089.
26. Ruttman E, Fischler N, Sakic A, Chevtchik O, Alber H, Schistek R, Ulmer H, Grimm M. Second internal thoracic artery versus radial artery in coronary artery bypass grafting: a long-term, propensity score-matched follow-up study. *Circulation*. 2011;124:1321–1329.
27. Santarpino G, Onorati F, Cristodoro L, Scalas C, Mastroberto P, Renzulli A. Radial artery graft flowmetry is better than saphenous vein on postero-lateral wall. *Int J Cardiol*. 2010;143:158–164.

28. Schwann TA, Hashim SW, Badour S, Obeid M, Engoren M, Tranbaugh RF, Bonnell MR, Habib RH. Equipose between radial artery and right internal thoracic artery as the second arterial conduit in left internal thoracic artery-based coronary artery bypass graft surgery: a multi-institutional study†. *Eur J Cardiothorac Surg*. 2016;49:188–195.
29. Stevens LM, Carrier M, Perrault LP, Hébert Y, Cartier R, Bouchard D, Fortier A, El-Hamamsy I, Pellerin M. Single versus bilateral internal thoracic artery grafts with concomitant saphenous vein grafts for multivessel coronary artery bypass grafting: effects on mortality and event-free survival. *J Thorac Cardiovasc Surg*. 2004;127:1408–1415.
30. Tarelli G, Mantovani V, Maugeri R, Chelazzi P, Vanoli D, Grossi C, Ornaghi D, Panisi P, Sala A. Comparison between single and double internal mammary artery grafts: results over ten years. *Ital Heart J*. 2001;2:423–427.
31. Tranbaugh RF, Dimitrova KR, Friedmann P, Geller CM, Harris LJ, Stelzer P, Cohen B, Hoffman DM. Radial artery conduits improve long-term survival after coronary artery bypass grafting. *Ann Thorac Surg*. 2010;90:1165–1172.
32. Tranbaugh RF, Schwann TA, Swistel DG, Dimitrova KR, Al-Shaar L, Hoffman DM, Geller CM, Engoren M, Balaram SK, Puskas JD, Habib RH. Coronary Artery Bypass Graft Surgery Using the Radial Artery, Right Internal Thoracic Artery, or Saphenous Vein as the Second Conduit. *Ann Thorac Surg*. 2017;104:553–559.
33. Tsuneyoshi H, Komiya T, Shimamoto T, Sakai J, Hiraoka T, Kawashima T, Muraoka G, Fujimoto M, Yamanaka K. The second best arterial graft to the left coronary system in off-pump bypass surgery: a propensity analysis of the radial artery with a proximal anastomosis to the ascending aorta versus the right internal thoracic artery. *Gen Thorac Cardiovasc Surg*. 2015;63:335–342.
34. Yoshida S, Numata S, Tsutsumi Y, Monta O, Yamazaki S, Seo H, Samura T, Ohashi H. Short- and long-term results of radial artery and saphenous vein grafts in the right coronary system: a propensity-matched study. *Surg Today*. 2017;47:335–343.
35. Zacharias A, Habib RH, Schwann TA, Riordan CJ, Durham SJ, Shah A. Improved survival with radial artery versus vein conduits in coronary bypass surgery with left internal thoracic artery to left anterior descending artery grafting. *Circulation*. 2004;109:1489–1496.